POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (9.21.2021, 5:41pam CEST, WHO):   India 26,115    Brazil 9,458    United Kingdom 35,702    Russia 19,179    Turkey 27,688    Iran 17,397    Columbia 1,813    Italy 2,405    Indonesia 3,263    Germany 4,664    Mexico 4,983    South Africa 1,504    Philippines 18,937    Ukraine 5,159    Malaysia 14,345    Netherlands 1,370    Iraq 3,192    Japan 2,405    Bangladesh 1,562    Thailand 10,919    Pakistan 2,167    Romania 6,789    Morocco 2,246    Serbia 6,424    Jordan 1,075    Cuba 8,544    Nepal 1,036    Austria 1,162    Vietnam 8,681    Greece 2,124    Georgia 2,470    Belarus 1,941    Costa Rica 1,627    Bulgaria 2,360    Myanmar 1,687    Palestine 3,909    Croatia 1,037    Ireland 1,150    Libya 1,081    Lithuania 1,157    South Korea 1,729    Mongolia 2,543    Botswana 1,536    El Salvador 2,323    China 83    Singapore 0    New Zealand 15    Australia 1,515   

Pig trial of AstraZeneca's coronavirus vaccine shows promise with two shots

Christian Fernsby |
A trial in pigs of AstraZeneca's experimental coronavirus vaccine has found that two doses of the shot produced a greater antibody response than a single dose.

Article continues below



Topics: ASTRAZENECA   

Research released by Britain's Pirbright Institute on Tuesday found that giving an initial prime dose followed by a booster dose of the vaccine elicited a stronger immune response than a single dose.

This suggests a two-dose approach may be more effective in getting protection against coronavirus, the disease caused by the new coronavirus.

"The researchers saw a marked increase in neutralising antibodies, which bind to the virus in a way that blocks infection," the Pirbright team said in a statement.

They added, however, that it is not yet known what level of immune response will be required to protect humans.

The ChAdOx1 nCoV-19 vaccine, also known as AZD1222, was originally developed by Oxford University scientists, who are now working with AstraZeneca on development and production.

"These results look encouraging that administering two injections ...

boosts antibody responses that can neutralise the virus, but it is the response in humans that's important," said Bryan Charleston, Pirbright's director.

AZD1222 is already in human trials, and AstraZeneca says it hopes to have data on efficacy later this year.

Preliminary data from a trial in six monkeys found that some of the monkeys given a single shot developed antibodies against the virus within 14 days, and all developed protective antibodies within 28 days.


What to read next

3-in-1 vaccine against traveler's diarrhea
Zika vaccine works in early human trial
Experimental Ebola vaccines elicit year-long immune response